| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2123878 | European Journal of Cancer | 2010 | 9 Pages |
Abstract
We confirmed the expression of COX-2 in 65% of chondrosarcomas, and COX-2 inhibition by celecoxib diminished cell viability in vitro. The initial response and the decrease in tumour volume with increased celecoxib serum levels in vivo supported a role for celecoxib, although relapsed tumour growth after 6Â weeks was worrisome. Also the role of high-dose prophylactic celecoxib in preventing the development of benign and malignant cartilage tumours in EC and MO patients deserves further investigation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Y.M. Schrage, I. Machado, D. Meijer, I. Briaire-de Bruijn, B.E. van den Akker, A.H.M. Taminiau, T. Kalinski, A. Llombart-Bosch, J.V.M.G. Bovée,